Immunis.AI Announces Publication, in The Journal of Urology, of Results from Blood-Based Immune Profiling Study for Prostate Cancer Patients
The results validate the ability of the platform to accurately stratify risk for patients with diagnosed prostate cancer.
- The results validate the ability of the platform to accurately stratify risk for patients with diagnosed prostate cancer.
- “One of the big challenges in prostate cancer management is distinguishing those patients with early prostate cancer who are appropriate for active surveillance from those who need to be aggressively treated.
- In the study, peripheral blood samples were collected from 706 subjects with confirmed prostate cancer based on positive biopsy.
- Using AI predictive modeling, the normalized immune profile of each patient was evaluated against known immune signatures for indolent or aggressive prostate cancer.